Paul J. Glazer Discloses 2.47M Shares of scPharmaceuticals in Schedule 13G

Rhea-AI Filing Summary

Glazer Capital, LLC and its Managing Member Paul J. Glazer filed a Schedule 13G reporting shared beneficial ownership of 2,474,820 shares of scPharmaceuticals Inc. common stock, representing 4.64% of the class. The filing notes the shares are held by funds and managed accounts for which Glazer Capital serves as investment manager and that the Reporting Persons do not assert sole voting or dispositive power over these shares. The statement also indicates that the Reporting Persons have ceased to be beneficial owners of more than 5% of the class.

Positive

• Transparent disclosure of the shareholding and classification under Schedule 13G
• Clear statement that the position is not held to influence control, consistent with passive investor treatment

Negative

• Concentrated shared voting/dispositive power of 2,474,820 shares could still represent an influential block despite being 4.64% of the class

Insights

Securities Analyst

TL;DR: A passive 4.64% stake is disclosed; no indication of control or activist intent.

The filing shows Glazer Capital and Paul J. Glazer jointly hold 2,474,820 shares, equal to 4.64% of scPharmaceuticals (CUSIP 810648105). All voting and dispositive power is reported as shared, with zero sole power, and the certification states the position is not intended to influence control. Because the stake is below 5% and the filing is on Schedule 13G, this is treated as a passive, non-control disclosure under the Exchange Act. Materiality is limited given the sub-5% ownership and explicit non-control statement.

Corporate Governance Expert

TL;DR: Transparent disclosure of a modest passive stake; governance impact appears minimal.

The Report identifies Glazer Capital (Delaware LLC) and Paul J. Glazer (U.S. citizen) as Reporting Persons and specifies shared voting and dispositive power for 2,474,820 shares. The filing’s language and use of Schedule 13G indicate a passive investment relationship rather than an active campaign for control. From a governance perspective, shareholders and the board should note the position size but would not typically treat this as a takeover or activist signal given the stated intent and the sub-5% threshold.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

scPharmaceuticals Inc.

(Name of Issuer)

Common stock, par value $0.0001 per share

(Title of Class of Securities)

810648105

(CUSIP Number)

09/02/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 810648105

1

Names of Reporting Persons

Glazer Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,474,820.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,474,820.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,474,820.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.64 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 810648105

1

Names of Reporting Persons

Paul J. Glazer

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,474,820.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,474,820.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,474,820.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.64 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: scPharmaceuticals Inc.
(b)	Address of issuer's principal executive offices: 25 Mall Road, Suite 203, Burlington, Massachusetts, 01803
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Glazer Capital, LLC, a Delaware limited liability company ("Glazer Capital"), with respect to the shares of Common Stock (as defined in Item 2(d)) held by certain funds and managed accounts to which Glazer Capital serves as investment manager (collectively, the "Glazer Funds"); and (ii) Mr. Paul J. Glazer ("Mr. Glazer"), who serves as the Managing Member of Glazer Capital, with respect to the shares of Common Stock held by the Glazer Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock (as defined in Item 2(d)) reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is 250 West 55th Street, Suite 30A, New York, New York 10019.
(c)	Citizenship: Glazer Capital is a Delaware limited liability company. Mr. Glazer is a United States citizen.
(d)	Title of class of securities: Common stock, par value $0.0001 per share
(e)	CUSIP No.: 810648105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2,474,820
(b)	Percent of class: 4.64%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 2,474,820
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 2,474,820
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Reporting Persons may have been deemed to beneficially own more than 5% of the outstanding shares on the date of event that required the filing of the Schedule 13G. As of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Glazer Capital, LLC

Signature:	Paul J. Glazer
Name/Title:	Paul J. Glazer, Managing Member
Date:	09/09/2025

Paul J. Glazer

Signature:	Paul J. Glazer
Name/Title:	Paul J. Glazer
Date:	09/09/2025

FAQ

How many scPharmaceuticals (SCPH) shares do Glazer Capital and Paul J. Glazer report owning?

The Reporting Persons disclose shared beneficial ownership of 2,474,820 shares, representing 4.64% of the class.

Does the Schedule 13G filing indicate Glazer Capital seeks to influence control of SCPH?

No; the filing includes a certification that the securities were not acquired to change or influence control and was filed on Schedule 13G indicating passive intent.

What voting and dispositive powers are reported by the filers for SCPH shares?

The filers report 0 sole voting power, 2,474,820 shared voting power, 0 sole dispositive power, and 2,474,820 shared dispositive power.

Has Glazer Capital exceeded the 5% ownership threshold in SCPH?

No; the filing states the Reporting Persons have ceased to be beneficial owners of more than 5%, and the reported ownership is 4.64%.

Which entity and individual signed the Schedule 13G for SCPH?

The filing is signed by Glazer Capital, LLC and Paul J. Glazer (Managing Member), dated 09/09/2025.